Filtering by:
TreatmentFDA Approves Ayvakit (Avapritinib) for GIST
The US Food and Drug Administration (FDA) has approved Ayvakit (avapritinib) to treat people with advanced cases of gastrointestinal stromal tumor (GIST) that have a certain genetic mutation.
FDA Approves Padcev (Enfortumab vedotin-ejfv) for Bladder Cancer
The US Food and Drug Administration (FDA) has approved a new type of drug for certain people with bladder cancer.
2019 in Review: New Cancer Drug Approvals
In 2019, the FDA approved several new drug treatments for different cancer types. Here are the stories that made headlines on cancer.org this year.
2019 in Review: Top 10 Cancer News Stories
In 2019 we published stories about new findings in cancer risk factors, prevention, treatment, and survivorship issues. Here are the 10 most significant stories that made headlines on cancer.org this year.
FAQ: Caregiving During Chemotherapy
Taking care of someone getting chemotherapy can involve helping to make treatment decisions and many other tasks. Knowing what to expect as a caregiver allows you to be helpful while taking care of your own needs too. Learn the basics.
FAQ: Caregiving During Radiation Treatment
It’s normal to have questions about how to help someone getting radiation treatment. Read the answers to some of the more common ones here. For more help call us at 1-800-227-2345.
Study: Hormone Treatment for Prostate Cancer Linked With Dementia
Researchers from the University of Pennsylvania found that older prostate cancer patients getting hormone treatment, called androgen deprivation therapy (ADT), were more likely to be diagnosed later with Alzheimer’s disease or dementia.
Patients with a Late Diagnosis of Metastatic Cancer May Be Overtreated
Nearly 30% of people who died within 1 month of being diagnosed with an incurable cancer got aggressive treatment that may have been ineffective, according to a new American Cancer Society (ACS) study. The study's lead author was Helmneh M. Sineshaw, MD, MPH, a principal scientist in health services at the ACS.